STOCK TITAN
  1. Home
  2. News
  3. ESTA

Establishment Labs Holdings Inc. - ESTA STOCK NEWS

Welcome to our dedicated page for Establishment Labs Holdings news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Holdings stock.

Establishment Labs Holdings Inc. (ESTA) is a leading global medical technology company, renowned for its innovation in the field of medical devices and aesthetics. Specializing in advanced silicone-filled breast and body shaping implants, the company has over 30 years of experience in breast implant manufacturing. Establishment Labs designs, develops, manufactures, and markets an extensive product portfolio that ensures safety and meets the current needs and preferences of plastic surgeons and patients.

Known for its flagship product, Motiva Implants®, Establishment Labs has set a benchmark in the industry for product innovation and safety. The company operates in multiple geographical segments, including Europe, Latin America, Asia-Pacific/Middle East, and other regions. Establishment Labs' products are distributed to medical distributors, physicians, hospitals, and clinics through direct sales channels.

Recent achievements include the continued global expansion of the Motiva Implants® brand and strategic partnerships aimed at advancing medical and aesthetic technology. With a strong focus on the future, the company is dedicated to pushing the boundaries of innovation and safety in medical devices.

Establishment Labs maintains a robust financial condition, driven by its commitment to quality and continuous improvement. The company’s ongoing projects include research and development initiatives aimed at introducing new and improved products that align with market demands.

For the latest updates and relevant information about Establishment Labs Holdings Inc., stay tuned to this page for the most recent news and developments.

News

Establishment Labs Announces Commercial Launch of Motiva Implants in China

Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced the launch of Motiva® Implants in China, the second largest market globally. The company expects rapid growth in China due to consumer appreciation for innovative technologies and a large segment willing to pay a premium for such products. The commercial launch coincided with the Motiva China International Academic Conference, and events also took place in Shanghai, Guangzhou, and Shenzhen. Establishment Labs received National Medical Products Administration (NMPA) approval in China for Motiva® Implants in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
none
-
News

Establishment Labs Announces $50 Million Private Placement and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2023

Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced a securities purchase agreement with institutional accredited investors to purchase common shares or pre-funded warrants. Preliminary unaudited financial results for Q4 2023 show expected revenue in the range of $31.4 million to $31.8 million, in line with previous guidance. Full-year 2023 revenue is expected to be $165.0 million to $165.4 million, with a year-end cash position of approximately $39.1 million. The company will sell two million common shares or pre-funded warrants at $25.00 per share, expecting aggregate gross proceeds of approximately $50 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
earnings
-
News

Establishment Labs Announces First U.S. Commercial Procedure with Motiva Flora Tissue Expander

Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that the Motiva Flora® SmoothSilk® Tissue Expander was used for the first time in the United States at the University of Texas MD Anderson Cancer Center in Houston by Mark Clemens, MD MBA FACS, Professor of Plastic Surgery. The recent FDA clearance and first procedure mark significant developments in the field of plastic and reconstructive surgery. The Flora® Tissue Expander includes several proprietary innovations, including Establishment Labs’ patented SmoothSilk® surface technology and an RFID-enabled, non-magnetic port, labeled as MR Conditional by the FDA. SmoothSilk® has been shown to produce the least amount of inflammation and foreign body response compared to other device surfaces. By being magnet-free, Flora avoids the interference that magnets cause during MRI and may improve the precision of radiation oncology treatment. Juan José Chacón-Quirós, Founder and CEO of Establishment Labs, emphasized the company's commitment to improving women’s health and wellness, stating that real innovation leads to better patient outcomes, and Flora is setting a new standard in breast reconstruction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none
News

Establishment Labs to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announces participation in the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences
-
News

Establishment Labs Announces Participation in Two Upcoming Investment Conferences

Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announces participation in two investment conferences, including the 2023 Jefferies London Healthcare Conference and the Stephens Annual Investment Conference. CEO and Founder Juan José Chacón-Quirós and CFO Raj Denhoy will speak at the events, with live webcasts available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
none
-
News

Establishment Labs Announces National Medical Products Administration Approval for Motiva Implants in China

Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has received NMPA approval in China for Motiva® Implants, marking their entry into the second largest global market for breast aesthetics. The company expects Chinese plastic surgeons to adopt their technology as their first choice, based on their success in South Korea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.32%
Tags
none
News

Establishment Labs Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) Announces Q3 2023 Financial Results: Revenue Up 0.8%, 2023 Revenue Guidance Increased to $165 Million, Loss from Operations Increases, FDA Clearance for Motiva Flora® SmoothSilk® Tissue Expander, Mia Femtech™ Clinical Study Data Released
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.18%
Tags
earnings
-
News

Establishment Labs to Announce Third Quarter 2023 Financial Results on November 7

Rhea-AI Summary
Flora, the magnet-free and MR Conditional tissue expander, has been cleared for the U.S. market. Establishment Labs Holdings Inc. plans to announce its financial results for Q3 2023 on November 7, 2023, and will host a conference call to discuss those results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
earnings
-
News

Establishment Labs Announces FDA Clearance of Motiva Flora SmoothSilk Tissue Expander

Rhea-AI Summary
Establishment Labs receives FDA clearance for Motiva Flora® SmoothSilk® Tissue Expander
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.25%
Tags
clinical trial
News

Establishment Labs Announces Two-Year Mia Femtech Clinical Results and the Launch of Zen at 8th World Symposium on Ergonomic Implants

Rhea-AI Summary
Establishment Labs announces two-year clinical results of Mia Femtech and launch of Zen RFID technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
clinical trial

FAQ

What is the current stock price of Establishment Labs Holdings (ESTA)?

The current stock price of Establishment Labs Holdings (ESTA) is $40.01 as of December 20, 2024.

What is the market cap of Establishment Labs Holdings (ESTA)?

The market cap of Establishment Labs Holdings (ESTA) is approximately 1.1B.

What does Establishment Labs Holdings Inc. specialize in?

Establishment Labs specializes in designing, developing, manufacturing, and marketing advanced silicone-filled breast and body shaping implants.

What is the flagship product of Establishment Labs?

The flagship product of Establishment Labs is Motiva Implants®, known for its safety and innovation.

In which regions does Establishment Labs operate?

Establishment Labs operates in Europe, Latin America, Asia-Pacific/Middle East, and other regions.

How does Establishment Labs distribute its products?

The company distributes its products through direct sales to medical distributors, physicians, hospitals, and clinics.

What are the recent achievements of Establishment Labs?

Recent achievements include global expansion of the Motiva Implants® brand and strategic partnerships to advance medical and aesthetic technology.

What is the focus of Establishment Labs' ongoing projects?

Ongoing projects focus on research and development to introduce new and improved products that meet market demands.

How long has Establishment Labs been in the breast implant manufacturing industry?

Establishment Labs has over 30 years of experience in the breast implant manufacturing industry.

What sets Motiva Implants® apart from other products in the market?

Motiva Implants® are known for their innovation, safety, and alignment with the needs and preferences of plastic surgeons and patients.

Is Establishment Labs a publicly traded company?

Yes, Establishment Labs Holdings Inc. is a publicly traded company with the symbol ESTA.

Where can I find the latest news about Establishment Labs Holdings Inc.?

You can find the latest news and updates about Establishment Labs Holdings Inc. on this webpage and from reliable financial news sources.

Stock ESTA logo
Establishment Labs Holdings Inc.

Nasdaq:ESTA

ESTA Rankings

#2435 Ranked by Market Cap
N/A Ranked by Dividends

ESTA Stock Data

1.12B
25.28M
11.28%
98.89%
17.16%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
ALAJUELA